Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

INTRODUCTION: Previous trials demonstrated that anti-angiogenesis or anti-programmed death protein 1 (PD-1) monotherapy showed unsatisfied effect in advanced hepatocellular carcinoma (HCC). No study existed that focus on the effects of camrelizumab and apatinib (“C+A”) combination therapy for HCC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Guosheng, Cheng, Xiao, Li, Qi, Zang, Mengya, Huang, Wei, Fan, Wenzhe, Wu, Tao, Ruan, Jian, Dai, Wencong, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Hu, Xiaoyun, Chen, Jinzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734076/
https://www.ncbi.nlm.nih.gov/pubmed/33328740
http://dx.doi.org/10.2147/OTT.S286169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734076/
https://www.ncbi.nlm.nih.gov/pubmed/33328740
http://dx.doi.org/10.2147/OTT.S286169

Ejemplares similares